1 / 1
Motixafortide is a synthetic CXCR4 antagonist peptide developed to mobilize hematopoietic stem cells (HSCs) for autologous transplantation and is also being studied in oncology and immunotherapy.
Motixafortide blocks the CXCR4–SDF-1 axis, leading to:
Rapid stem cell mobilization into peripheral blood
Enhanced immune cell trafficking and tumor infiltration
Potential synergy with checkpoint inhibitors and chemotherapy
High-purity synthetic peptide
GMP-like production standards
Suitable for injectable formulations
Motixafortide API supports advanced research in stem cell therapy and cancer immunotherapy.
Motixafortide API is a synthetic CXCR4 antagonist peptide designed to mobilize hematopoietic stem cells (HSCs) into peripheral blood for autologous transplantation and oncology research.
It blocks the CXCR4–SDF-1 axis, which induces rapid stem cell mobilization, enhances immune cell trafficking, increases tumor infiltration, and offers potential synergistic effects with chemotherapy and checkpoint inhibitors.
Clinical trials have shown that Motixafortide demonstrates superior stem cell yield when compared to existing mobilization therapies.
The API features high-purity synthetic peptide quality, adheres to GMP-like production standards, and is specifically suitable for injectable formulation development.
Motixafortide API is used to advance research in hematopoietic stem cell therapy, autologous stem cell transplantation, and cancer immunotherapy.
